secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001453687-24-000084
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics receives FDA RMAT designation for Descartes-08 in myasthenia gravis
--------------------------------------------------------------------------------

- FDA granted RMAT designation for Descartes-08, an autologous mRNA CAR-T therapy targeting BCMA for myasthenia gravis.
- RMAT designation provides fast track and breakthrough therapy benefits, enabling expedited FDA interactions and development.
- Topline data from Phase 2b randomized, double-blind, placebo-controlled trial of Descartes-08 in MG expected mid-2024.
- Descartes-08 previously received FDA Orphan Drug Designation for MG.
- Phase 2a data (Jan 2024) showed durable autoantibody depletion and clinically meaningful MG severity score improvements over 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000084/0001453687-24-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000084/rnac-20240522.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer